System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Eve Maubec is an expert in Dermatology at Assistance Publique - Hôpitaux de Paris (France). As of October 2026, ScienceLeadR ranks Eve Maubec in the top 1% of experts worldwide for Non-Melanoma Skin Neoplasms, Skin Neoplasms and Melanoma. Eve Maubec has authored 334 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 3 of them ongoing. SLR score: 1,008 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Eve Maubec Assistance Publique - Hôpitaux de Paris France
1 008 ScienceLeadR Reputation 1008

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Assistance Publique - Hôpitaux de Paris

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 334

Citations

Citations: 6 356 1st author: 33 Last author: 51 Unique author: 3

Main journals

Ann Dermatol Venereol 98
Annales de Dermatologie et de Vénéréologie - FMC 30
J Clin Oncol 29
Annales de dermatologie et de vénéréologie, FMC 22
Br J Dermatol 14

Best Journals

J Clin Oncol 10
Ann Oncol 7
Nature 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.
PMID 41806521 — cells, safety, carcinoma, squamous cell, neoplasms, therapeutics		Eur J Cancer20260
[Open data: main objective achieved for the French Society of Pathology's data challenges].
PMID 41577495 — melanoma, pathology, wounds and injuries, cervix uteri		Ann Pathol20260
Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study.
PMID 41396687 — skin, cells, safety, melanoma, neoplasms, sarcoma, immune checkpoint inhibitors, hiv, therapeutics, skin neoplasms		Oncologist20250
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).
PMID 40912206 — sexually transmitted diseases, lymph nodes, melanoma, retrospective studies, covid-19, lymph, diagnosis, pandemics, therapeutics, dermatology		Ann Dermatol Venereol20250
Avelumab plus cetuximab in advanced cutaneous squamous cell carcinoma: a strategy to overcome resistance to PD-1 blockade.
PMID 40838805 — cells, syphilis, cetuximab, carcinoma, squamous cell, dermatology, cutaneous squamous cell carcinoma		Br J Dermatol20250

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

N/A 6
Phase 2 3
Phase 1 1

By status:

Completed 4
Recruiting 4
Not yet recruiting 1
Unknown 1

By type:

Interventional 5
Observational 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri scar Dermatoheliosis as a Predictive Factor of Response to Anti PD 1
NCT05856565 — skin, intelligence, cicatrix, melanoma, neoplasms, algorithms, immunotherapy, photography, therapeutics, artificial intelligence		N/ARecruiting2023
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High risk of Recurrence
NCT05062096 — skin, cells, blood, killer cells, natural, melanoma, neoplasms, biopsy, immunotherapy, therapeutics, mutation		N/ANot yet recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS